Zydus Lifesciences
Zydus Lifesciences Limited is an Indian pharmaceutical enterprise that discovers, develops, manufactures, and markets a broad portfolio of human formulations, active pharmaceutical ingredients, and wellness products globally. The company operates through primary business segments including Finished Dosage Formulations, Active Pharmaceutical Ingredients, Consumer Wellness, and Animal Health. Its principal revenue drivers stem from high-volume sales of generic prescription medicines, specialty biopharmaceuticals, biosimilars, and over-the-counter consumer wellness products across North America, India, and emerging international markets. Zydus Lifesciences holds a leading position in the Indian pharmaceutical industry and maintains an established commercial footprint in the United States generic drug market. The enterprise focuses on expanding research and development in novel chemical entities, advancing biosimilar clinical trials, optimizing pharmaceutical manufacturing efficiency, and securing global regulatory approvals. Zydus Lifesciences Limited is headquartered in Ahmedabad, India, and its common stock is publicly listed and traded on the National Stock Exchange of India and the BSE.
14 of the funds FundTelligence covers report a position in Zydus Lifesciences.
- Legal name
- Zydus Lifesciences Ltd
- Sector
- Health Care
- Country
- India
- Funds holding it
- 14
Funds holding Zydus Lifesciences
- Handelsbanken Emerging Markets Index — Handelsbanken · 0.12 % (full portfolio disclosed, September 2026)
- Storebrand Emerging Markets — Storebrand · 0.11 % (full portfolio disclosed, October 2026)
- Nordea Emerging Markets Enhanced — Nordea Funds · 0.11 % (full portfolio disclosed, September 2026)
- KLP AksjeFremvoksende Markeder Flerfaktor — KLP · 0.09 % (full portfolio disclosed, June 2026)
- Storebrand Emerging Markets Plus — Storebrand · 0.08 % (full portfolio disclosed, October 2026)
- Storebrand Indeks Nye Markeder — Storebrand · 0.04 % (full portfolio disclosed, October 2026)
- BlackRock iShares MSCI EM IMI Screened UCITS ETF — BlackRock · 0.02 % (full portfolio disclosed, October 2026)
- Mercer Passive Emerging Markets Equity Fund — Mercer · 0.02 % (full portfolio disclosed, December 2025)
Showing the 8 largest of 14 funds holding it.